Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Acurx Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Acurx Pharmaceuticals şirketinin toplam hissedar öz sermayesi $3.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $6.6M ve $3.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$6.36m
Eşitlik	US$3.43m
Toplam yükümlülükler	US$3.15m
Toplam varlıklar	US$6.58m

Son finansal sağlık güncellemeleri

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Aug 11

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13

Recent updates

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Aug 11

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Jan 22

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Oct 30

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Jul 15

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Mar 04

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Nov 16

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Jul 25

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

May 13

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Jan 22

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

Sep 30

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Aug 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ACXP 'nin kısa vadeli varlıkları ( $6.6M ) kısa vadeli yükümlülüklerini ( $3.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: ACXP un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ACXP borçsuzdur.

Borcun Azaltılması: ACXP un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ACXP şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: ACXP un, serbest nakit akışı her yıl % 29.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Acurx Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Recent updates

Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Insufficient new directors

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

Price target decreased by 10% to US$10.88

Acurx Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

New major risk - Revenue and earnings growth

Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

Forecast to breakeven in 2026

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

Acurx Pharmaceuticals, Inc. Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global Scientific Conference

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 17, 2024

Acurx Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 15, 2024

Acurx Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering.

Acurx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

Acurx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Acurx Pharmaceuticals, Inc. Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2B Clinical Trial in Cdi Patients

Independent Director exercised options to buy US$75k worth of stock.

Acurx Sell-Off Presents Opportunity Before Upcoming Data Release

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients

Co-Founder exercised options to buy US$77k worth of stock.

Acurx Pharmaceuticals, Inc. Announces Positive Phase 2B Results Showing 100% of Patients Who Has Clinical Cure with Ibezapolstat Also Has Sustained Clinical Cure

Acurx Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

New major risk - Financial position

Acurx Pharmaceuticals, Inc. Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. Difficile Infection

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New major risk - Share price stability

Acurx Pharmaceuticals, Inc. Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

New major risk - Revenue and earnings growth

Acurx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?

Acurx Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 12, 2023

Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acurx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI At the 16Th Biennial Congress of the Anaerobe Society of America

Acurx Pharmaceuticals, Inc. announced a financing transaction

Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering

Acurx Pharmaceuticals, Inc.(NasdaqCM:ACXP) dropped from Russell Microcap Value Index

Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Acurx Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2022

Acurx Pharmaceuticals, Inc. Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases

Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation

Acurx Announces First Patient Enrolled in Phase 2B Clinical Trial of Its Lead Antibiotic for Treatment of Clostridioides Difficile Infection (CDI)

Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth

New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers

Acurx Pharmaceuticals, Inc. has completed an IPO in the amount of $15 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin